CHELMSFORD, Mass.--(BUSINESS WIRE)--Aug 20, 2012--ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today it has entered into an agreement to license Inovise Medical, Inc.’s ambulatory AUDICOR ® technology as part of the advanced patient diagnostics in the LifeVest ® Wearable Defibrillator.
According to the American Heart Association, an estimated 83 million Americans are currently living with cardiovascular disease (CVD). CVD is responsible for one-third of all deaths annually, or over 2,200 deaths per day, in the US. 1 The risk of sudden cardiac death is the highest in the days and weeks following an acute cardiac event and during the period of medical therapy optimization, such as adjusting a pharmacologic regimen to treat heart failure.
The LifeVest Wearable Defibrillator is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing medical condition, and until their permanent risk of SCA is established. The LifeVest protects these patients during this time of highest risk while they are being optimized on medical therapy. A patient’s condition can improve from the benefits of medical therapy, including meaningful improvement in ejection fraction.
With the addition of the advanced diagnostic features from Inovise, LifeVest will be able to expand the suite of clinically meaningful patient information available to physicians and clinicians to support clinical decisions. In addition to ambulatory monitoring of ECG (electrocardiography), Inovise Medical’s AUDICOR technology analyzes heart sounds (acoustic cardiography) to provide more diagnostic capabilities and aid in assessing acute and chronic cardiac function for conditions such as heart failure and related comorbidities.
“The integration of the advanced diagnostic technologies from Inovise with the LifeVest platform further emphasizes our ongoing commitment to providing physicians and clinicians with clinically meaningful tools to improve patient management and outcomes,” said Marshal Linder, President of ZOLL LifeVest.
Peter Bauer, President of Inovise Medical, added, “Inovise’s AUDICOR technology was developed through years of focused clinical research and algorithm development. We are pleased that, in conjunction with the success of ZOLL’s LifeVest product line, physicians and clinicians will have access to our advanced diagnostics to monitor patients during the most vulnerable stages of their cardiac recovery. Inovise is proud to provide the benefits of our ambulatory diagnostic technology to the life-saving therapy of the LifeVest.” About Inovise Medical Inovise Medical, Inc., of Portland, Oregon, is a privately held company founded in 1997, which is focused on advanced cardiac technology. Inovise Medical's technology includes advanced ECG algorithms for improved myocardial infarction detection and AUDICOR, which evaluates the performance of the heart by analyzing heart sounds and cardiac timing intervals.
AUDICOR enables clinicians to non-invasively and rapidly assess cardiac patients to aid in early diagnosis and/or to adjust treatment. AUDICOR technology is used both in EMS and hospitals for diagnostics and in clinics for managing heart failure therapy. Recent advances of the technology have been made in ambulatory monitoring of heart failure patients to aid in differential diagnoses and treatment optimization. Additional information on Inovise Medical, Inc. and AUDICOR ® technology may be found at http://www.audicor.com.
About ZOLL Medical Corporation ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care. For more information, visit www.zoll.com.
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 25,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.
Copyright © 2012 ZOLL Medical Corporation. All rights reserved. LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.
1 Roger VL, et al.; Circulation. 2012;125:188-197CONTACT: ZOLL Medical Corporation Diane Egan, +1 978-421-9637 firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: TECHNOLOGY HARDWARE SOFTWARE HEALTH CARDIOLOGY HOSPITALS MEDICAL DEVICES MEDICAL SUPPLIES SOURCE: ZOLL Medical Corporation Copyright Business Wire 2012 PUB: 08/20/2012 05:03 PM/DISC: 08/20/2012 05:03 PM http://www.businesswire.com/news/home/20120820006329/